Life Healthcare Group (0928) AI Stock Analysis

• Market Cap: HK$185.04M
• Dividend Yield: N/A
• Average Volume (3M): 760.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: -58.65%
• EPS Growth: -370.13%
• Country: HK
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): <0.01
• Shares Outstanding: 1,850,425,000
• 10 Day Avg. Volume: 724,000
• 30 Day Avg. Volume: 760,773
• PEG Ratio: <0.01
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 1.32
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ―

Life Healthcare Group's stock is supported by strong financial recovery and undervaluation, making it potentially attractive to value investors. However, persistent cash flow issues and bearish technical indicators present risks and may result in continued stock pressure. The company must focus on improving liquidity to enhance its long-term outlook.

Positive Factors

Financial Stability

A strong equity ratio and low debt-to-equity ratio suggest that the company is financially stable, providing a solid foundation for future growth and resilience against economic fluctuations.

Strategic Partnerships

The strategic partnership with Mingyuan aims to enhance market penetration and brand value in Mainland China, potentially leading to increased revenue and competitive positioning over the long term.

Board Restructuring

The restructuring of the board and establishment of committees can enhance governance and operational oversight, potentially improving decision-making and strategic direction.

Negative Factors

Compliance Challenges

Non-compliance with listing rules due to board changes may affect investor confidence and require swift action to restore compliance, impacting the company's governance reputation.

Legal Disputes

Ongoing legal disputes related to unauthorized agreements could lead to financial losses and distract management, potentially affecting the company's operational focus and reputation.

Cash Flow Challenges

Persistent negative cash flows indicate challenges in converting earnings into cash, which could impact the company's ability to invest in growth opportunities and meet financial obligations.

Life Healthcare Group Business Overview & Revenue Model

Company Description

King International Investment Ltd. is a holding company, which engages in providing healthcare products and services business. It operates through the following segments: Healthcare Products and Services Business, Money Lending Business, and Sales of Liquor Business. It also operates through the People’s Republic of China and Hong Kong geographical segments. The company was founded on March 12, 2001 and is headquartered in Hong Kong.

How the Company Makes Money

Life Healthcare Group generates revenue primarily through its hospital operations, which include patient fees for medical treatments, surgeries, and other healthcare services provided at its facilities. Diagnostic services contribute significantly to its income, with fees charged for laboratory tests and imaging services. The company may also earn from partnerships with healthcare technology firms, enhancing service offerings through innovative solutions. Revenue streams are further supported by investments in healthcare infrastructure projects, yielding returns through long-term leases or service contracts. Strategic collaborations with governmental and private entities can also bolster income through funding and shared service agreements.

Life Healthcare Group Financial Statement Overview

Summary

Life Healthcare Group shows strong recovery in revenue and profitability, with significant improvements in income statement metrics. The balance sheet is robust with low leverage and high equity, indicating financial stability. However, cash flow challenges persist, with negative operating and free cash flows, necessitating strategic focus for improvement.

Income Statement

The company shows a positive trend with significant revenue growth from previous years, alongside improvements in gross profit and net income, indicating a recovery from prior losses. The gross profit margin is healthy at 16.2%, and the net profit margin has improved to 6.8%. The positive EBIT and EBITDA margins further underline the return to profitability. However, the volatility in historical EBIT and EBITDA suggests some operational unpredictability.

Balance Sheet

The balance sheet reflects strong equity, with a high equity ratio of 80.3%, indicating financial stability. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage risk. The return on equity has improved significantly to 5.9%, a positive sign of increasing shareholder value. Despite these strengths, the decrease in cash and short-term investments over time might pose liquidity concerns.

Cash Flow

While the company has shown improvement in cash flow metrics, the negative operating and free cash flows in recent years are concerning, especially with a free cash flow of -32.3 million in the latest year. The operating cash flow to net income ratio is negative, indicating challenges in converting earnings into cash. The trend of negative cash flows needs addressing to ensure long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.77M	40.77M	233.68M	223.85M	92.87M	102.04M
Gross Profit	1.01M	12.73M	37.79M	12.05M	13.75M	26.23M
EBITDA	-21.27M	-10.01M	27.69M	-26.72M	-29.18M	9.68M
Net Income	-47.45M	-47.45M	15.82M	-25.19M	-34.46M	-4.58M
Balance Sheet
Total Assets	286.36M	286.36M	336.13M	264.27M	302.94M	325.01M
Cash, Cash Equivalents and Short-Term Investments	309.00K	309.00K	473.00K	17.79M	37.40M	8.57M
Total Debt	2.37M	2.37M	5.71M	6.73M	422.00K	715.00K
Total Liabilities	63.72M	63.72M	70.08M	31.27M	39.56M	30.32M
Stockholders Equity	222.64M	222.64M	269.85M	237.50M	262.28M	290.58M
Cash Flow
Free Cash Flow	77.00K	0.00	-32.32M	-134.69M	96.85M	-181.34M
Operating Cash Flow	77.00K	0.00	-32.32M	-134.48M	96.86M	-181.34M
Investing Cash Flow	0.00	0.00	1.00K	94.86M	-67.83M	-34.46M
Financing Cash Flow	-493.00K	0.00	17.39M	27.40M	-830.00K	28.29M

Life Healthcare Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0928, the sentiment is Positive. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.09, and above the 200-day MA of 0.09, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.80 is Neutral, neither overbought nor oversold. The STOCH value of 43.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0928.

Life Healthcare Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$197.21M	11.19	7.84%	8.00%	-21.50%	-43.25%
0928	58 Neutral	HK$185.04M	-4.81	-15.25%	―	-58.65%	-370.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8225	48 Neutral	HK$143.33M	-10.00	-16.17%	―	19.97%	76.51%
0673	43 Neutral	HK$816.87M	-5.91	-465.55%	―	-17.39%	-45.76%
8143	42 Neutral	HK$193.90M	-6.44	-132.60%	―	-30.45%	-734.38%

Life Healthcare Group Corporate Events

King International Investment Limited Announces Annual General Meeting and Key Resolutions

King International Investment Limited has announced its upcoming annual general meeting scheduled for January 9, 2026. The meeting will address several key resolutions, including the adoption of audited financial statements, re-election of executive and non-executive directors, and the reappointment of auditors. Additionally, the company seeks approval to allot and issue new shares, which could impact its capital structure and shareholder value.

Coastal Greenland Limited Announces Change in Share Registrar Office

Coastal Greenland Limited, a company incorporated in the Cayman Islands, has announced a change in its Hong Kong Branch Share Registrar and Transfer Office. Effective from December 16, 2025, the company will transition its services to Tricor Investor Services Limited. This change is expected to streamline the registration and transfer of shares, potentially impacting shareholders who will need to direct future share-related applications to the new office.

King International Appoints New Co-Chairman to Boost Healthcare Strategy

King International Investment Limited has announced the appointment of Mr. Wang Jun as an executive director and co-chairman of the board, effective December 4, 2025. Mr. Wang brings extensive experience in biotechnology, regenerative medicine, and international financial markets, and is known for pioneering concepts such as ‘life asset management’ and ‘financialisation of life data.’ His appointment is expected to enhance the company’s competitiveness and growth potential in the healthcare sector.

King International Investment Limited Announces New Board Composition

King International Investment Limited, a company incorporated in the Cayman Islands, has announced the composition of its board of directors effective from December 4, 2025. The board includes both executive and independent non-executive directors, with Mr. Leng Yueyingtan and Mr. Wang Jun serving as co-chairmen. The board has established four committees: Audit, Nomination, Remuneration, and Fund Management, with various directors assigned as members or chairmen, indicating a structured governance approach.

King International Investment Limited Reports Strong Interim Results for 2025

King International Investment Limited, a company incorporated in the Cayman Islands, has announced its interim results for the six months ended 30 September 2025. The company reported a significant increase in revenue, reaching HK$73,919,000 compared to HK$37,186,000 in the same period in 2024. This resulted in a gross profit of HK$7,800,000, up from HK$1,009,000 the previous year. The company achieved a profit before tax of HK$9,251,000, a substantial improvement from a loss of HK$1,553,000 in 2024. The total comprehensive income for the period was HK$12,162,000, highlighting a strong financial performance and positive outlook for stakeholders.

King International Investment Limited Schedules Board Meeting for Interim Results

King International Investment Limited, incorporated in the Cayman Islands, has announced a board meeting scheduled for November 28, 2025. The meeting will focus on approving the company’s interim results for the six months ending September 30, 2025, which could have implications for the company’s financial performance and investor relations.

King International Partners with Rongyuhe Group for Strategic Growth

King International Investment Limited has announced a strategic cooperation agreement with Rongyuhe Group Hong Kong Limited. This partnership aims to explore opportunities in the health industry, shopping malls, and baijiu business sectors, leveraging Rongyuhe Group’s expertise in the digital economy. The collaboration is expected to enhance King International’s competitiveness and sustainable development, aligning with its overall development strategy.